Literature DB >> 22294272

Brain tumors in children--current therapies and newer directions.

Soumen Khatua1, Zsila Sousan Sadighi, Michael L Pearlman, Sunil Bochare, Tribhawan S Vats.   

Abstract

Brain tumors are the second most common malignancy and the major cause of cancer related mortality in children. Though significant advances in neuroimaging, neurosurgery, radiation therapy and chemotherapy have evolved over the years, overall survival rate remains less than 75%. Malignant gliomas, high risk medulloblastoma with recurrence and infant brain tumors continue to be a major cause of therapeutic frustration. Even today diffuse pontine gliomas are universally fatal. Though tumors like low grade glioma have an overall excellent survival, recurrences and progression in eloquent areas pose therapeutic challenges. As research continues to unravel the biology including key molecules and signaling pathways responsible for the oncogenesis of different childhood brain tumors, novel targeted therapies are profiled. Identification of major targets like the Epidermal Growth factor Receptor (EGFR), Platelet Derived Growth Factor Receptor (PDGFR), Vascular Endothelial Growth factor (VEGF) and key signaling pathways like the MAPK and PI3K/Akt/mTOR has enabled us over the recent years to better understand tumor behavior and design tailored therapy. These efforts have improved overall survival of children with brain tumors. This review article discusses the current status of common brain tumors in children and the newer therapeutic approaches.

Entities:  

Mesh:

Year:  2012        PMID: 22294272     DOI: 10.1007/s12098-012-0689-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  38 in total

1.  Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.

Authors:  C Raffel; L Frederick; J R O'Fallon; P Atherton-Skaff; A Perry; R B Jenkins; C D James
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

Review 3.  Neuroimaging in neuro-oncology.

Authors:  Soonmee Cha
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Medulloblastoma in young children.

Authors:  Stefan Rutkowski; Bruce Cohen; Jonathan Finlay; Roberto Luksch; Vita Ridola; Dominique Valteau-Couanet; Junichi Hara; Maria-Luisa Garre; Jacques Grill
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

5.  Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.

Authors:  M Bredel; I F Pollack; R L Hamilton; C D James
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

6.  Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

Authors:  Katherine E Warren; Stewart Goldman; Ian F Pollack; Jason Fangusaro; Paula Schaiquevich; Clinton F Stewart; Dana Wallace; Susan M Blaney; Roger Packer; Tobey Macdonald; Regina Jakacki; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

7.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Authors:  Margaret J Dougherty; Mariarita Santi; Marcia S Brose; Changqing Ma; Adam C Resnick; Angela J Sievert; Phillip B Storm; Jaclyn A Biegel
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

Review 8.  Convection-enhanced delivery: targeted toxin treatment of malignant glioma.

Authors:  Walter A Hall; Gregory T Sherr
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

9.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

10.  Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.

Authors:  Nongnuch Sirachainan; Samart Pakakasama; Anannit Visudithbhan; Surang Chiamchanya; Lojana Tuntiyatorn; Mantana Dhanachai; Jiraporn Laothamatas; Suradej Hongeng
Journal:  Neuro Oncol       Date:  2008-06-16       Impact factor: 12.300

View more
  11 in total

Review 1.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

2.  STAT3 is a key molecule in the oncogenic behavior of diffuse intrinsic pontine glioma.

Authors:  Jinju Park; Woochan Lee; Sangil Yun; Saet Pyoul Kim; Kyung Hyun Kim; Jong-Il Kim; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

3.  The impact of surgical resection of giant supratentorial brain tumor in pediatric patients: safety and neurological outcome evaluated in 23 consecutive cases.

Authors:  Ricardo Santos de Oliveira; Danilo Jorge Pinho Deriggi; Luciano L Furlanetti; Marcelo Volpon Santos; Elvis Terci Valera; Maria Sol Brassesco; Hélio Rubens Machado
Journal:  Childs Nerv Syst       Date:  2014-11-06       Impact factor: 1.475

4.  Detection of irreversible changes in susceptibility-weighted images after whole-brain irradiation of children.

Authors:  S Peters; R Pahl; A Claviez; O Jansen
Journal:  Neuroradiology       Date:  2013-04-16       Impact factor: 2.804

5.  Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.

Authors:  Juan C Espinoza; Kelley Haley; Neha Patel; Girish Dhall; Sharon Gardner; Jeffrey Allen; Joseph Torkildson; Albert Cornelius; Rod Rassekh; Antranik Bedros; Morris Etzl; James Garvin; Kamnesh Pradhan; Robin Corbett; Michael Sullivan; Geoffrey McGowage; Dagmar Stein; Rama Jasty; Stephen A Sands; Lingyun Ji; Richard Sposto; Jonathan L Finlay
Journal:  Pediatr Blood Cancer       Date:  2016-06-22       Impact factor: 3.167

6.  Spectrum of pediatric brain tumors: a report of 341 cases from a tertiary cancer center in India.

Authors:  Umesh Das; L Appaji; B S Aruna Kumari; Nagesh T Sirsath; M Padma; S Kavitha; T Avinash; K C Lakshmaiah
Journal:  Indian J Pediatr       Date:  2014-04-15       Impact factor: 1.967

Review 7.  Improving Care in Pediatric Neuro-oncology Patients: An Overview of the Unique Needs of Children With Brain Tumors.

Authors:  Cheryl Fischer; Mary Petriccione; Maria Donzelli; Elaine Pottenger
Journal:  J Child Neurol       Date:  2015-08-05       Impact factor: 1.987

8.  Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.

Authors:  Ricardo Cabanas; Giselle Saurez; Martha Rios; Jose Alert; Adnolys Reyes; Jose Valdes; Maria C Gonzalez; Jorge L Pedrayes; Melba Avila; Raiza Herrera; Mariela Infante; Ernesto Echevarria; Myrna Moreno; Patricia Lorenzo Luaces; Tania Crombet Ramos
Journal:  MAbs       Date:  2013 Mar-Apr       Impact factor: 5.857

Review 9.  Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors.

Authors:  Juliette Servante; Jasper Estranero; Lisethe Meijer; Rob Layfield; Richard Grundy
Journal:  Oncotarget       Date:  2018-10-16

10.  Childhood cancers: what is a possible role of infectious agents?

Authors:  Kenneth Alibek; Assel Mussabekova; Ainur Kakpenova; Assem Duisembekova; Yeldar Baiken; Bauyrzhan Aituov; Nargis Karatayeva; Samal Zhussupbekova
Journal:  Infect Agent Cancer       Date:  2013-12-10       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.